Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective. 

The new study included data on patients who presented for TAVR with preexisting AFib as well as those who developed new-onset AFib after the procedure. 

Hospitals should be making every effort to help sonographers deliver better, more accurate echocardiograms and improve the diagnosis of severe aortic stenosis. If you take care of your sonographers, your sonographers will take care of you. 

“The Evolut FX system is an improvement over previous Evolut system devices and it delivers better overall results to our patients,” says interventional cardiologist Guilherme Attizzani, MD. “It is an ideal solution for a majority of our patients.”

Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.

The company behind the new technology was recently acquired for approximately $253 million. 

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

Hospital readmissions, ER visits and major complications were all less likely when TAVR patients used a smartphone app to assist with their recovery.